Epitope specificity and IgG subclass distribution of autoantibodies to cardiac troponin. 2013

Tanja Savukoski, and Aleksandra Twarda, and Sanna Hellberg, and Noora Ristiniemi, and Saara Wittfooth, and Juha Sinisalo, and Kim Pettersson
Department of Biotechnology, University of Turku, Turku, Finland. tanja.savukoski@utu.fi

BACKGROUND Autoantibodies to cardiac troponins (cTnAAbs) can interfere with the measurement of cardiac troponin I (cTnI) by immunoassays for the diagnosis of myocardial infarction. Therefore, we determined the cTnI binding sites and IgG subclasses of circulating cTnAAbs. METHODS We studied epitope specificity with sandwich-type immunoassays by measuring the recovery of troponin complex added to 10 cTnAAb-negative and 10 cTnAAb-positive sera from healthy volunteers. To study the IgG subclasses, we analyzed admission and 3-month follow-up sera from chest pain patients with a reference assay measuring total IgG (14 cTnAAb negative and 14 cTnAAb positive at 3 months) and with 4 subclass-specific assays measuring exclusively IgG subclasses 1-4. RESULTS Mean recoveries of troponin complex in cTnAAb-positive samples for single cTnI epitopes ranged from 37% to 211%, being lowest for the cTnI midfragment (aa 30-110). However, the lowest sample-specific recoveries, 4%-92%, showed that none of the studied epitopes completely escaped the cTnAAb-related interference. Eight chest pain patients of the cTnAAb-positive group became positive between sampling points, and according to all 5 cTnAAb assays, specific signals were generally higher at follow-up. IgG4, with the highest prevalence, was detected in 68% of samples in the cTnAAb-positive group. CONCLUSIONS IgG subclass studies confirm that cTnAAb formation may be triggered/boosted in acute cardiac events. This new information about the epitope specificity of cTnAAbs should be used to reevaluate existing recommendations regarding use of midfragment epitopes in cTnI assays. To circumvent the negative interference of the highly heterogeneous cTnAAbs, use of 3 or more unconventionally selected epitopes should be considered.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D007118 Immunoassay A technique using antibodies for identifying or quantifying a substance. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance. Immunochromatographic Assay,Assay, Immunochromatographic,Assays, Immunochromatographic,Immunoassays,Immunochromatographic Assays
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000918 Antibody Specificity The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site. Antibody Specificities,Specificities, Antibody,Specificity, Antibody
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic
D001323 Autoantibodies Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them. Autoantibody
D019210 Troponin I A TROPONIN complex subunit that inhibits ACTOMYOSIN ATPASE activity thereby disrupting ACTIN and MYOSIN interaction. There are three troponin I subtypes: troponin I1, I2 and I3. Troponin I3 is cardiac-specific whereas troponin I1 and I2 are skeletal subtypes. Troponin I3 is a BIOMARKER for damaged or injured CARDIAC MYOCYTES and mutations in troponin I3 gene are associated with FAMILIAL HYPERTROPHIC CARDIOMYOPATHY. Troponin I1,Troponin I2,Troponin I3,Troponin-I

Related Publications

Tanja Savukoski, and Aleksandra Twarda, and Sanna Hellberg, and Noora Ristiniemi, and Saara Wittfooth, and Juha Sinisalo, and Kim Pettersson
January 1986, Scandinavian journal of rheumatology,
Tanja Savukoski, and Aleksandra Twarda, and Sanna Hellberg, and Noora Ristiniemi, and Saara Wittfooth, and Juha Sinisalo, and Kim Pettersson
November 1986, Immunology letters,
Tanja Savukoski, and Aleksandra Twarda, and Sanna Hellberg, and Noora Ristiniemi, and Saara Wittfooth, and Juha Sinisalo, and Kim Pettersson
January 1989, Monographs in allergy,
Tanja Savukoski, and Aleksandra Twarda, and Sanna Hellberg, and Noora Ristiniemi, and Saara Wittfooth, and Juha Sinisalo, and Kim Pettersson
January 1986, The Journal of investigative dermatology,
Tanja Savukoski, and Aleksandra Twarda, and Sanna Hellberg, and Noora Ristiniemi, and Saara Wittfooth, and Juha Sinisalo, and Kim Pettersson
January 1988, Journal of clinical immunology,
Tanja Savukoski, and Aleksandra Twarda, and Sanna Hellberg, and Noora Ristiniemi, and Saara Wittfooth, and Juha Sinisalo, and Kim Pettersson
March 2005, Clinical and experimental immunology,
Tanja Savukoski, and Aleksandra Twarda, and Sanna Hellberg, and Noora Ristiniemi, and Saara Wittfooth, and Juha Sinisalo, and Kim Pettersson
June 1991, Clinical and experimental immunology,
Tanja Savukoski, and Aleksandra Twarda, and Sanna Hellberg, and Noora Ristiniemi, and Saara Wittfooth, and Juha Sinisalo, and Kim Pettersson
April 2007, Journal of neuroimmunology,
Tanja Savukoski, and Aleksandra Twarda, and Sanna Hellberg, and Noora Ristiniemi, and Saara Wittfooth, and Juha Sinisalo, and Kim Pettersson
January 1988, Nephron,
Tanja Savukoski, and Aleksandra Twarda, and Sanna Hellberg, and Noora Ristiniemi, and Saara Wittfooth, and Juha Sinisalo, and Kim Pettersson
February 1988, Clinical immunology and immunopathology,
Copied contents to your clipboard!